Items Tagged ‘Adult Acute Lymphoblastic Leukemia’

July 18th, 2016

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment

By

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology is an emerging treatment technique that has demonstrated significant effectiveness in the treatment […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia, B cell acute lymphoblastic leukemia, CAR technology, Clinical Trials Database, deaths, fda, Fludara, fludarabine, Leukemia, News, ROCKET trial


October 10th, 2014

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

By

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, fda, Leukemia, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


October 6th, 2008

Relapsed or Refractory Adult ALL

By

Overview Patients with progressive or relapsed adult ALL remain curable despite failing initial treatment. Patients failing treatment can be divided into two broad categories. Patients who fail to achieve an initial complete disappearance or remission of their cancer following a complete course of remission induction chemotherapy treatment are referred to as “induction failures”. Patients who […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia


October 1st, 2008

Adult Acute Lymphoblastic Leukemia: Post-Remission Treatment

By

Overview If a complete remission is achieved following remission induction therapy and no further treatment given, over 90% of patients will have a recurrence of leukemia in weeks to months. However, treatment with standard intensive post-remission therapy can now cure 25-35% of adults with ALL. It is important to understand what determines the success or […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia


October 1st, 2008

Adult Acute Lymphoblastic Leukemia: Remission Induction

By

Overview Researchers have learned that the best way to cure patients with adult ALL is to administer large doses of several chemotherapeutic drugs over a short period of time. The concept is to kill leukemia cells quickly before resistance to the drugs occurs. Therapy is divided into two phases, remission induction and post-remission therapy. Remission […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia


October 1st, 2008

Adult Acute Lymphoblastic Leukemia

By

Overview Adult ALL is a malignant disease or cancer of the blood characterized by the rapid uncontrolled growth of abnormal, immature white blood cells known as lymphoblasts. There are approximately 5,000 new cases of Adult ALL each year in the US with approximately 1500 deaths. There has been significant progress in treating adult ALL over […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia, Leukemia